What is Leerink Partnrs’ Estimate for TNDM FY2028 Earnings?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Equities research analysts at Leerink Partnrs increased their FY2028 EPS estimates for shares of Tandem Diabetes Care in a report released on Wednesday, April 30th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will post earnings of $0.42 per share for the year, up from their previous estimate of $0.31. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s FY2029 earnings at $0.88 EPS.

TNDM has been the subject of several other reports. Morgan Stanley cut shares of Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $45.00 to $22.00 in a report on Wednesday, March 5th. Wells Fargo & Company reduced their price target on Tandem Diabetes Care from $22.00 to $20.00 and set an “equal weight” rating for the company in a report on Thursday. Royal Bank of Canada dropped their price objective on Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. Sanford C. Bernstein downgraded Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $35.00 to $25.00 in a report on Friday, February 28th. Finally, Canaccord Genuity Group upped their price target on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a “buy” rating in a research note on Thursday. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.81.

Tandem Diabetes Care Price Performance

Shares of NASDAQ:TNDM opened at $21.48 on Friday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care has a one year low of $15.75 and a one year high of $53.69. The company has a 50-day simple moving average of $18.80 and a 200-day simple moving average of $28.57. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -11.13 and a beta of 1.52.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. During the same quarter last year, the firm earned ($0.65) EPS. The business’s revenue was up 22.3% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TNDM. Vanguard Group Inc. lifted its stake in shares of Tandem Diabetes Care by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company’s stock valued at $267,989,000 after purchasing an additional 77,451 shares during the period. ArrowMark Colorado Holdings LLC lifted its stake in Tandem Diabetes Care by 14.1% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company’s stock valued at $98,108,000 after buying an additional 337,026 shares during the period. GW&K Investment Management LLC grew its position in shares of Tandem Diabetes Care by 18.0% during the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company’s stock worth $76,488,000 after buying an additional 323,674 shares during the period. Stephens Investment Management Group LLC increased its stake in shares of Tandem Diabetes Care by 9.7% in the 1st quarter. Stephens Investment Management Group LLC now owns 1,706,915 shares of the medical device company’s stock valued at $32,704,000 after acquiring an additional 151,106 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of Tandem Diabetes Care by 189.0% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company’s stock valued at $59,830,000 after acquiring an additional 1,086,337 shares during the period.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos bought 10,538 shares of Tandem Diabetes Care stock in a transaction dated Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, with a total value of $190,948.56. Following the acquisition, the chief operating officer now directly owns 10,538 shares of the company’s stock, valued at $190,948.56. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.90% of the stock is currently owned by insiders.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.